Manor Moshe 4
4 · Protalix BioTherapeutics, Inc. · Filed Sep 14, 2018
Insider Transaction Report
Form 4
Manor Moshe
President & CEO
Transactions
- Award
Stock Options (Right to Buy)
2018-09-13+1,300,000→ 1,300,000 totalExercise: $0.56Exp: 2028-09-13→ Common Stock (1,300,000 underlying)
Footnotes (2)
- [F1]The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.
- [F2]Does not include options to purchase 900,000 shares of common stock at an exercise price equal to $2.37 per share that expire on September 29, 2024.